• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

Skin Clearance

Almirall
March 27, 2022
Pharmaceutical News

Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies

BARCELONA, Spain, More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual

More
Almirall
Pharmaceutical News

Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Pivotal Phase 3 Atopic Dermatitis Studies

March 27, 2022

BARCELONA, Spain, More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease

More
  • APAC overview: trends, challenges, and possibilities for growth in the MarTech sector
  • Modernizing Therapeutic Cell Production
  • Neuraxpharm completes its presence in Benelux
  • Pharma Mirror Q&A with Jane Myles, Vice President of Clinical Trial Innovation at Curebase
  • Leg Veins: Why They Appear and How Vein Doctors Treat Them?

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop